Compare TG Therapeutics Inc (TGTX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Advanced Drainage Systems Inc — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.83B). The key difference: Advanced Drainage Systems Inc is the larger of the two by market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | WMS | |
|---|---|---|
Market Cap | $7.64B | $10.83B |
Sector | Health | Industrials |
52-Week High | $59.06 | $175.38 |
52-Week Low | $26.94 | $129.50 |
Enterprise Value | $7.84B | $12.44B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
WMS trades at $140.22, down 1.02% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news highlights Q1 2027 revenue growth of 21% year-over-year and a quarterly dividend declaration.
The outlook is mixed: analyst consensus is a Buy with a $185.86 price target, implying upside, but technical weakness and a Zacks Strong Sell rating (June 22, 2026) pose near-term risks. Investment appeal hinges on execution of growth initiatives amid competitive pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
